BiomX (PHGE) announced the successful initiation of patient dosing in the Company’s Phase 2b trial with first patient dosed. The trial is evaluating BX004 for the treatment of cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa infections, which remain a leading cause of death in this patient population despite modern treatments. Pending topline results expected in the first quarter of 2026, BX004 could potentially be positioned as the leading phage-based therapy for CF patients with these deadly infections.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHGE: